Blood Disorder News and Research

RSS
Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Hydroxyurea plus aspirin best therapy in patients with essential thrombocythemia who are at high risk for vascular events

Experimental drug PKC412 may be the key to treating myeloproliferative disease

Experimental drug PKC412 may be the key to treating myeloproliferative disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.